Literature DB >> 18385362

Pharmacokinetics of dihydroartemisinin in a murine malaria model.

Kevin T Batty1, Peter L Gibbons, Timothy M E Davis, Kenneth F Ilett.   

Abstract

Pharmacokinetic properties of dihydroartemisinin (DHA) were determined in mice given 100 mg/kg intraperitoneal DHA. Half-life, CL/F, and V/F were 25 min, 61.3 L/hr/kg, and 36.3 L/kg in malaria-infected mice and 19 min, 50.9 L/hr/kg, and 23.0 L/kg in controls. These data are valuable for pharmacokinetic-pharmacodynamic evaluations of DHA in murine models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385362

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  Impact of Extended Duration of Artesunate Treatment on Parasitological Outcome in a Cytocidal Murine Malaria Model.

Authors:  Leah A Walker; David J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.

Authors:  Kashyap Patel; Kevin T Batty; Brioni R Moore; Peter L Gibbons; Jürgen B Bulitta; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

3.  JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium.

Authors:  Geoffrey W Birrell; Marina Chavchich; Arba L Ager; Hong-Ming Shieh; Gavin D Heffernan; Wenyi Zhao; Peter E Krasucki; Kurt W Saionz; Jacek Terpinski; Guy A Schiehser; Laura R Jacobus; G Dennis Shanks; David P Jacobus; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

4.  Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment.

Authors:  Georges F R Radohery; Annabelle Walz; Christin Gumpp; Mohammed H Cherkaoui-Rbati; Nathalie Gobeau; Jeremy Gower; Miles P Davenport; Matthias Rottmann; James S McCarthy; Jörg J Möhrle; Maria Rebelo; Claudia Demarta-Gatsi; David S Khoury
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

5.  A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia.

Authors:  Harpreet Singh; Anang A Shelat; Amandeep Singh; Nidal Boulos; Richard T Williams; R Kiplin Guy
Journal:  J Biomol Screen       Date:  2013-08-29

6.  Pharmacokinetics of artemisinin delivered by oral consumption of Artemisia annua dried leaves in healthy vs. Plasmodium chabaudi-infected mice.

Authors:  Pamela J Weathers; Mostafa A Elfawal; Melissa J Towler; George K Acquaah-Mensah; Stephen M Rich
Journal:  J Ethnopharmacol       Date:  2014-03-22       Impact factor: 4.360

7.  Potent in vivo anti-malarial activity and representative snapshot pharmacokinetic evaluation of artemisinin-quinoline hybrids.

Authors:  Marli C Lombard; David D N'Da; Christophe Tran Van Ba; Sharon Wein; Jennifer Norman; Lubbe Wiesner; Henri Vial
Journal:  Malar J       Date:  2013-02-21       Impact factor: 2.979

8.  A murine malaria protocol for characterizing transmission blocking benefits of antimalarial drug combinations.

Authors:  Yehenew A Ebstie; Alain R Tenoh Guedoung; Annette Habluetzel
Journal:  Malariaworld J       Date:  2020-04-01

9.  Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model.

Authors:  Suresh B Lakshminarayana; Céline Freymond; Christoph Fischli; Jing Yu; Sebastian Weber; Anne Goh; Bryan K S Yeung; Paul C Ho; Véronique Dartois; Thierry T Diagana; Matthias Rottmann; Francesca Blasco
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

10.  The Artemiside-Artemisox-Artemisone-M1 Tetrad: Efficacies against Blood Stage P. falciparum Parasites, DMPK Properties, and the Case for Artemiside.

Authors:  Liezl Gibhard; Dina Coertzen; Janette Reader; Mariëtte E van der Watt; Lyn-Marie Birkholtz; Ho Ning Wong; Kevin T Batty; Richard K Haynes; Lubbe Wiesner
Journal:  Pharmaceutics       Date:  2021-12-03       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.